ISSN: 2451-0629
Archives of Medical Science - Atherosclerotic Diseases
Current volume Archive About the journal Abstracting and indexing Contact Instructions for authors
Official journal of the International Lipid Expert Panel (ILEP)
CALL FOR PAPERS
1/2019
vol. 4
 
Share:
Share:
more
 
 
Clinical research

The effects of levosimendan use on high-sensitivity C-reactive protein in patients with decompensated heart failure

Hasan Korkmaz
,
Mücahid Yilmaz

Arch Med Sci Atheroscler Dis 2019; 4: e174–e179
Online publish date: 2019/07/22
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

The decrease of cardiac stroke volume to the level that the metabolic needs of the tissues cannot be met causes the symptoms of heart failure. Heart failure often occurs in the course of different cardiovascular diseases, at the final stage of these diseases, and is considered to be an important cause of mortality and morbidity [1]. Despite the improvements in treatment, the 5-year mortality rate is approximately 60% and this rate is higher than the mortality rate of most malignancies [2].

Inotropic agents are drugs that are used in the treatment of acute heart failure, where systolic dysfunction is accompanied by peripheral hypoperfusion or hypotension [3]. It was reported that the main mechanism of action of levosimendan in increasing myocardial contractility was based on increasing the susceptibility of cardiac troponin-C to cytoplasmic calcium [4]. Recent studies indicated that C-reactive protein (CRP) and high-sensitivity C-reactive protein (hsCRP) were risk factors for heart failure [5, 6]. Moreover, studies suggested that hsCRP could be accepted as an independent indicator of mortality in patients with heart failure [7]. Higher CRP levels are associated with more severe heart failure. The relationship between CRP and heart failure was explained with the high filling pressures of the left ventricle [5].

It is unclear how levosimendan infusion affects serum hsCRP levels. The present study aimed to investigate whether levosimendan use affects hsCRP levels in hospitalized patients with decompensated heart failure and in patients with heart failure under routine treatment.

Material and methods

The present study was designed as a prospective controlled clinical trial. A total of 50 patients with decompensated heart failure, who applied to the emergency department in our hospital and were admitted to the coronary intensive care unit, were included in the present study. Patients with stage III–IV heart failure based on the New York Heart Association (NYHA), with systolic blood pressure > 100 mm Hg and with left ventricular ejection fraction of < 35%, were selected for the study population. Patients who presented to the emergency department due to decompensated heart failure were admitted to the coronary intensive care unit and they were administered nasal oxygen, their venous blood was taken, and echocardiography was conducted on these patients. The patients were randomized to levosimendan (n = 25) and furosemide groups (n = 25). The patients in the levosimendan group received levosimendan infusion with a maintenance dose of 0.1 µg/kg/min (24 h). The dose was halved when hypotension developed in patients. The furosemide group received a 100 to 160 mg daily dose of furosemide intravenous infusion. The highest tolerable doses of angiotensin converting enzyme inhibitors (ACE), β-blockers, and low-dose spironolactone therapy were administered to each patient due to their clinical status. Optimal medical treatments were planned for all patients.

Transthoracic echocardiogram (ECO)

M-mode and 2D ECO were performed based on the American Society of Echocardiography criteria using 3.25 probes in a Vivid 3 ECO echocardiography device on the left side in the decubitus position. Parasternal short-long axial images with standard echocardiographic positions and apical 4-space images were used in the measurements and these images were used to obtain the ejection fraction (EF) measurements and left ventricular systolic-diastolic diameters by the Simpson method. Each measurement was repeated twice, and the mean values of the measurements were taken into consideration. For standardization purposes, all measurements were conducted by the same individual.

Blood measurements

Ten ml basal blood samples, required to measure the hsCRP content and control parametric values, such as electrolytes, CBC, liver (AST, ALT) and kidney functions (urea, creatinine), were drawn from both groups at the 24th, 48th and 72nd h using a cannula from the antecubital vein. The measurements were conducted with an OLYMPUS 2700 auto-analyzer and the results were recorded separately for each patient.

Ethics

The study was initiated after receiving the approval of the local ethics committee and written informed consents forms were received from all patients included in the present study. The study was conducted in accordance with the Declaration of Helsinki.

Exclusion criteria

Patients younger than eighteen with restrictive or hypertrophic cardiomyopathy, uncorrected valve stenosis, infection, hypotension (systolic and diastolic blood pressure < 100 /60 mm Hg), EF over 35%, severe hepatic impairment, severe renal failure (creatinine levels > 3.0 g/dl) and patients with acute coronary syndrome, uncontrolled hypertension, or chronic obstructive pulmonary disease (COPD) were not included in the study. Furthermore, after being randomized to groups, patients who required medication or device support were excluded from the study.

Statistical analysis

Statistical analyses were conducted with SPSS software for Windows version 17.0 (SPSS Inc., Chicago, USA). Continuous variables were expressed as mean ± standard deviation and the categorical variables were expressed as count and percentage. In order to determine whether the variable data exhibited normal distribution, the Kolmogorov-Smirnov test was used. The χ2 test was used for qualitative variables and Student’s t test was used for quantitative variables. A p-value < 0.05 was considered significant.

Results

No significant difference was found between the levosimendan and furosemide treatment groups based on demographic, baseline echocardiographic and basal laboratory data (Table I).

Table I

Baseline characteristics in the levosimendan-treated and furosemide groups

ParameterLevosimendanFurosemideP-value
Age [years]67 ±1069 ±90.674
Sex [male]1312NS
Arterial blood pressure systole [mm Hg]121 ±16118 ±140.467
Arterial blood pressure diastole [mm Hg]74 ±970 ±90.159
Heart rate [beats/min]78 ±1179 ±140.753
Height [cm]167 ±7166 ±70.513
Weight [kg]70 ±869 ±100.730
Body mass index [kg/m²]25 ±225 ±30.388
Atrial fibrillation, n (%)8 (32)9 (36)NS
Diabetes mellitus, n (%)4 (16)3 (12)NS
Hypertension, n (%)7 (28)8 (32)NS
COPD, n (%)4 (16)3 (12)NS
Disease duration [months]57 ±4358 ±37NS
Ischemic/non-ischemic, n10/159/16NS
History of myocardial infarction, n (%)4 (16)5 (20)NS
Bypass history, n (%)1 (4)2 (8)NS
Stent history, n (%)2 (8)4 (16)NS
Urea [mg/dl]49 ±1448 ±180.369
Creatinine [mg/dl]0.98 ±0.280.82 ±0.290.555
AST [U/l]25 ±726 ±140.782
ALT [U/l]26 ±631 ±70.286
Glucose [mg/dl]118 ±48121 ±740.929
White blood cells [× 109/l]7418 ±12616692 ±1320.802
Hematocrit (%)41 ±442 ±50.425
Platelet [× 109/l]207 ±52178 ±430.293
EF (%)27 ±525 ±50.849
Left ventricular diastolic diameter [mm]59 ±957 ±160.511
Left ventricular systolic diameter [mm]51 ±1048 ±160.453
Potassium [mEq/l]4.2 ±0.534 ±0.410.257
Sodium [mEq/l]139 ±3139 ±30.704

[i] NS – non-significant, COPD – chronic obstructive pulmonary disease.

Additionally, there was no difference in basal hsCRP (mg/l) levels between the levosimendan infusion and furosemide groups (9.99 ±6.2, 9.23 ±6.4, p = 0.66). However, the hs-CRP levels measured at the 24th h (38.34 ±32.1 vs. 12.97 ±12.3, p < 0.001), the 48th h (31.13 ±29.9 vs. 12.44 ±10.1, p = 0.003) and the 72nd h (27.41 ±26.9 vs. 9.89 ±8.4, p = 0.002) were significantly higher in the levosimendan infusion group than the furosemide group (Table II, Figure 1).

Table II

Changes in hsCRP values of levosimendan and furosemide groups

VariableHsCRP [mg/l]
Basal24th h48th h72nd h
Levosimendan9.99 ±6.238.34 ±32.131.13 ±29.927.41 ±26.9
Furosemide9.23 ±6.412.97 ±12.312.44 ±10.19.89 ±8.4
P-value0.659< 0.0010.0030.002
Figure 1

Change in hsCRP levels based on treatment groups

/f/fulltexts/AMSAD/37270/AMS-AD-4-37270-g001_min.jpg

Discussion

Intravenous positive inotropic agents play an important role in short-term treatment of decompensated heart failure due to left ventricular systolic dysfunction [8, 9]. However, there exists no ideal inotropic agent that is both effective and has a low side effect profile. Despite the provision of rapid symptomatic improvement, these agents could lead to mortality in the long term [8]. It was also reported that increased intracellular cAMP and Ca+ concentration due to the use of positive inotropic was cardiotoxic [10]. Such condition causes a further increase in the energy requirement of the cell and the oxygen consumption of the myocardium [10]. It was reported that the main action mechanism of levosimendan in increasing myocardial contractility was based on the increase in the susceptibility of cardiac troponin-C to cytoplasmic calcium [4]. Such interaction is assumed to provide the inotropic effect through stabilizing the calcium-induced structural changes in tropomyosin and strengthening the actin-myosin cross-bridges. The intracellular calcium level does not increase during this inotropic effect and this is the most significant characteristic; thus, significant side effects such as cardiac myocyte dysfunction and arrhythmia due to intracellular calcium increase caused by adrenergic inotropes are considered to be prevented. It was suggested that sensitization due to levosimendan was dependent on the calcium concentration; hence the contractile elements had inotropic effects in systole, whereas the diastolic relaxation was not impaired since the diastole calcium concentration was low [11].

C-reactive protein is a pentameric acute phase protein produced in the liver [12]. It is also mentioned that CRP could additionally be synthesized extrahepatically by neurons, atherosclerotic plaques, monocytes and lymphocytes [13]. Although it is not fully acknowledged how the synthesis is controlled in these regions, these synthesis regions have an effect on plasma CRP levels. Various studies have concluded that CRP predicts the risk of future cardiovascular diseases independently of the known risk factors in healthy individuals [14]. Although it is at a low level, the inflammatory reaction could be responsible for disease development and poor prognosis in patients with coronary artery disease, stroke, peripheral vascular disease and diabetes, and moreover, it was indicated that a certain benefit could be obtained with drugs that have anti-inflammatory effects such as statins. Due to the presence of inflammatory cytokines in patients with heart failure, the question as to whether these agents have effects on the development and progression of heart failure became a focus of interest. According to the cytokine hypothesis, heart failure partially progresses due to the cardiac and systemic effects of these cytokines. It was not fully explained whether CRP was the sole indicator of an underlying inflammatory response and tissue damage, or directly contributed to the development of the immune response, leading to further tissue damage that accelerated the advance towards heart failure. Studies indicated that higher hsCRP levels were associated with poorer prognoses even after the planning of treatment based on other risk factors in cardiovascular diseases that were not associated with myocardial necrosis. Furthermore, hsCRP determines the outcome independently of the infarction size or recurrent infarction in diseases associated with myocardial necrosis. Such findings supported the hypothesis that CRP contributed directly to disease progression, possibly through amplification of the existing inflammatory reaction. Various studies have reported that inflammatory markers were elevated in patients with heart failure. For instance, tumor necrosis factor α (TNF-α), soluble TNF receptor 1 and 2 or interleukin 6 (IL-6) increased in patients with heart failure and were associated with the severity of the heart failure and the increased cardiovascular mortality in follow-up [15, 16]. Several studies focusing on this topic have indicated that high levels of hsCRP had a prognostic value beyond the plasma B-type natriuretic peptide (BNP) values [1719]. In the study SURVIVE, BNP values decreased in the early periods of levosimendan infusion, and this finding was not proven to have a positive effect on 180-day mortality [20]. Another study suggested that high hsCRP values in heart failure patients resulted in twice the re-hospitalization and death risk [21].

The Val-HeFT study was considered the most prominent study that presented the effects of hsCRP on morbidity and mortality in heart failure. In the Val-HeFT study, it was observed that the patient population of 4000 with heart failure had an average hsCRP of 3.23 mg/l and the patients with higher hsCRP exhibited more severe heart failure symptoms (lower LVEF, higher NYHA and worse quality of life) and worse neurohormonal profiles (higher BNP, norepinephrine and aldosterone levels). Additionally, the study reported that the prognostic significance of hsCRP was independent of BNP and the etiology of heart failure [22]. In the literature, we did not find a study that aimed to investigate the effects of levosimendan on hsCRP. One study included hsCRP variations in the findings, although it did not aim to report the correlation between levosimendan and hsCRP. In this retrospective study, the effects of levosimendan, dobutamine and vasodilator treatment on ongoing myocardial injury in acute decompensated heart failure were compared. In the results section, it was reported that hsCRP increased from 43 ng/ml to 67 ng/ml at the 48th h subsequent to levosimendan administration [23].

In the present study, it was observed that hsCRP levels were higher at the 24th, 48th and 72nd h in the group of patients who received levosimendan infusion. This finding could be explained by the fact that the effectiveness of levosimendan lasted longer than 24 h and its pharmacological effects continued up to 1 week after the discontinuation of the drug [24]. The increase in hsCRP levels, which is an acute phase reactant, subsequent to levosimendan infusion when compared to the control group could be interpreted as an increased myocyte damage and/or inflammatory response. Nevertheless, accompanying analyses of TNF-α, soluble TNF receptor 1 and 2 and inflammatory markers such as IL-6 could help to report clearer findings. Given the studies that suggested adverse effects of hsCRP elevation on mortality, it becomes evident that the potential associations between the levosimendan infusion-induced systemic inflammatory response and its adverse effects on long-term mortality deserve a greater focus of interest in the cardiology community.

The main limitation to the study was the low number of cases in both groups. Other limitations are the lack of investigation for inflammatory cytokines such as TNF-α, IL-6, or IL-1β during the follow-up of patients and the lack of long-term follow-up of the patients.

In conclusion, the present study revealed that hsCRP levels measured in the levosimendan infusion group were high during the treatment of decompensated heart failure. The obtained findings suggested that levosimendan infusion could lead to possible cardiac myocyte damage and/or a possible increase in the systemic inflammatory response. A further study that focuses on the effects of levosimendan on long-term mortality could facilitate an answer to certain other questions once hsCRP levels are measured along with the measurements of extensive inflammatory markers.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Cleland JG, Khand A, Clark A , authors. The heart failure epidemic: exactly how big is it? Eur Heart J. 2001. 22:p. 623–6

2 

Stewart S , author. Prognosis of patients with heart failure compared with common types of cancer. Heart Fail Monit. 2003. 3:p. 87–94

3 

Nieminen MS, Böhm M, Cowie MR, et al. , authors. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005. 26:p. 384–416

4 

Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D , authors. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother. 2005. 6:p. 2741–51

5 

Williams ES, Shah SJ, Ali S, Na BY, Schiller NB, Whooley MA , authors. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail. 2008. 10:p. 63–9

6 

Kang S, Fan LY, Chen M, Li J, Liu ZM , authors. Relationship of high-sensitivity C-reactive protein concentrations and systolic heart failure. Curr Vasc Pharmacol. 2017. 15:p. 390–6

7 

Jackson CE, Haig C, Welsh P, et al. , authors. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail. 2016. 18:p. 1491–8

8 

Felker GM, O’Connor CM , authors. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001. 142:p. 393–401

9 

Cohn JN, Goldstein SO, Greenberg BH, et al. , authors. A dose dependent increase in mortality with vesnari none among patients with severe heart failure. N Engl J Med. 1998. 339:p. 1810–6

10 

Slawsky MT, Colucci WS, Gottlieb SS, et al. , authors. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000. 102:p. 2222–7

11 

Sorsa T, Heikkinen S, Abbott MB, et al. , authors. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem. 2001. 276:p. 9337–43

12 

Black S, Kushner I, Samols D , authors. C-reactive protein. J Biol Chem. 2004. 279:p. 48487–90

13 

Kuta AE, Baum LL , authors. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med. 1986. 164:p. 321–6

14 

Deveraj S, Kumaresan PR, Jialal I , authors. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol. 2004. 36:p. 405–10

15 

Tsutamato T, Hisanaga T, Wada A , authors. Interlukin-6 in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998. 31:p. 391–8

16 

Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M , authors. Plasma cytokin parameters and mortality in patients with chronic heart failure. Circulation. 2000. 102:p. 3060–7

17 

Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG , authors. Relationship of high-sensivity c-reaktif protein to prognosis and other prognosis marker in outpatients with heart failure. Am Heart J. 2007. 153:p. 1048–55

18 

Tang WH, Shrestha K, Van Lente F, et al. , authors. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol. 2008. 101:p. 370–3

19 

Ishikawa C, Tsutamoto T, Fujii M, Sakai H, Tanaka T, Horie M , authors. Prediction of mortality by high sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopaty. Circ J. 2006. 70:p. 857–63

20 

Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A , authors; SURVIVE Investigators , author. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol. 2009. 53:p. 2343–8

21 

Yin WH, Chen JW, Feng AN, Lin SJ, Young S , authors. Multimarker approach to risk stratication among patients with advanced chronic heart failure. Clin Cardiol. 2007. 30:p. 397–402

22 

Anand IS, Latini R, Florea VG, et al. , authors. C-reactive protein in heart failure. Prognostic value and effect of valsartan. Circulation. 2005. 112:p. 1428–34

23 

Gencer E, Doğan V, Öztürk MT, Nadir A, Musmul A, Cavuşoğlu Y , authors. Comparison of the effects of levosimendan dobutamine and vasodilator therapy on ongoing myocardial injury in acute decompensated heart failure. J Cardiovasc Pharmacol Ther. 2017. 22:p. 153–8

24 

Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ , authors. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002. 40:p. 465–71

Copyright: © 2019 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe